Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2019-10-30 Board/Management Inform…
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes announcements of financial results (press release for quarterly and nine months ended September 30, 2019) and a significant management change (appointment of a new Chief Medical Officer). The document does not contain full financial statements or detailed financial analysis itself but references a press release as an exhibit. The presence of management appointment details aligns with Board/Management Information filings. The document is not an Annual Report, Interim Report, or Earnings Release since it references a press release for financial results rather than providing the results itself. It is not a Regulatory Filing in the fallback sense because it contains substantive information about management changes and financial results announcements. Therefore, the best classification is Board/Management Information (MANG) due to the detailed disclosure of the new executive appointment and related compensation terms, combined with financial results announcement context typical in 8-K filings for management changes.
2019-10-30 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC. It is a registration statement under the Securities Act of 1933 for securities to be offered under employee benefit plans, specifically the Insmed Incorporated 2019 Incentive Plan and Non-Qualified Stock Option Inducement Awards. The document includes details about the securities being registered, calculation of registration fees, incorporation by reference of prior filings (10-K, 10-Q, 8-K), and indemnification provisions for directors and officers. It is not an annual report, earnings release, or any other financial report but a registration statement related to securities issuance for employee plans. This type of filing is a capital/financing update related to the registration of securities for issuance under employee stock plans. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-08-22 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 1, 2019, by Insmed Incorporated. It specifically mentions Item 2.02 "Results of Operations and Financial Condition," indicating the company issued a press release regarding financial results for the three and six months ended June 30, 2019. The document states that the press release is furnished as Exhibit 99.1 and clarifies that the information is not "filed" for purposes of Section 18 of the Exchange Act, which is typical language for earnings releases or press releases attached to 8-K filings. The document length is 3829 characters, which is relatively short and consistent with an earnings release announcement rather than a full financial report. There are no actual financial statements or detailed financial data included in the text, only a reference to the press release. Therefore, this document is best classified as an Earnings Release (ER) rather than an Interim Report (IR) or Annual Report (10-K).
2019-08-01 English
PRIMARY DOCUMENT
Director's Dealing
2019-06-26 English
PRIMARY DOCUMENT
Director's Dealing
2019-06-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.